Zanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2).A264718 It has been investigated for the treatment of HER2-positive solid tumors, including gastroesophageal, colorectal, and biliary tract cancers.A264718
In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.L51908,L51903
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Zanidatamab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Zanidatamab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Zanidatamab. |
| Estrone | Estrone may increase the thrombogenic activities of Zanidatamab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Zanidatamab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Zanidatamab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Zanidatamab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Zanidatamab. |
| Estriol | Estriol may increase the thrombogenic activities of Zanidatamab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Zanidatamab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Zanidatamab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Zanidatamab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Zanidatamab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Zanidatamab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Zanidatamab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Zanidatamab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Zanidatamab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Zanidatamab. |
| Equol | Equol may increase the thrombogenic activities of Zanidatamab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Zanidatamab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Zanidatamab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Zanidatamab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Zanidatamab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Zanidatamab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Zanidatamab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Zanidatamab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Zanidatamab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Zanidatamab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Zanidatamab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Zanidatamab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Zanidatamab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Zanidatamab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Zanidatamab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Zanidatamab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Zanidatamab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zanidatamab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Zanidatamab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Zanidatamab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Zanidatamab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Zanidatamab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Zanidatamab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Zanidatamab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Zanidatamab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zanidatamab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Zanidatamab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zanidatamab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Zanidatamab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Zanidatamab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zanidatamab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Zanidatamab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Zanidatamab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Zanidatamab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zanidatamab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Zanidatamab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Zanidatamab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Zanidatamab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Zanidatamab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Zanidatamab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Zanidatamab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Zanidatamab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Zanidatamab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Zanidatamab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Zanidatamab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Zanidatamab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Zanidatamab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Zanidatamab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Zanidatamab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Zanidatamab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Zanidatamab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Zanidatamab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Zanidatamab. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Zanidatamab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Zanidatamab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Zanidatamab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Zanidatamab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Zanidatamab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Zanidatamab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Zanidatamab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Zanidatamab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Zanidatamab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Zanidatamab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Zanidatamab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Zanidatamab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Zanidatamab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Zanidatamab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Zanidatamab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Zanidatamab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Zanidatamab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Zanidatamab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Zanidatamab. |
| Stamulumab | The risk or severity of adverse effects can be increased when Stamulumab is combined with Zanidatamab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Zanidatamab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Zanidatamab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Zanidatamab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Zanidatamab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Zanidatamab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Zanidatamab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Zanidatamab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Zanidatamab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Zanidatamab. |